Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna’s preclinical cystic fibrosis (CF) human bronchial epithelial ...
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with ...
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination ...
WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics, Inc. has successfully completed the Phase 1 multiple ascending dose (MAD) trial for SION-451 and plans to finalize the MAD cohort for SION-719, with interim results in healthy ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sionna Therapeutics Inc. priced ...
We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other top insider ...
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results